NKGen Biotech to Present at Investment Conference
NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biotechnology company that focuses on developing autologous, allogeneic, and CAR-NK cell therapeutics. The company has recently made an exciting announcement regarding an upcoming event. Paul Y. Song, MD, the Chairman and CEO of NKGen, will be participating in a virtual presentation and holding one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is set to take place from September 9-11.
Virtual Presentation Details
The virtual presentation is scheduled to start at 7:00 AM Eastern Time on September 9. Registered participants will be able to access it on-demand through the H.C. Wainwright conference portal. After the presentation is available, attendees will have the chance to submit their questions to NKGen. Additionally, Dr. Song will be available for virtual one-on-one meetings throughout the conference.
Company Overview
NKGen Biotech is committed to advancing treatments that harness natural killer cells, which play a crucial role in the body’s immune response. By concentrating on innovative NK cell therapeutics, the company aims to enhance patient outcomes in clinical settings. Based in California, NKGen is leading the way in the development of next-generation cancer therapies.
Innovative Approaches to Cancer Treatment
What sets NKGen apart is its dedication to creating effective cancer treatments through innovative methodologies. The use of CAR-NK cell therapies is especially significant, as these therapies utilize the body’s immune system to identify and destroy cancer cells. The company’s strategic focus is generating hopeful prospects for both patients and investors.
Investor Relations
For those interested in learning more about NKGen Biotech and its involvement in the conference, additional information can be found on the company’s website, particularly in the Investors section. A recorded version of the presentation will also be available after the event, providing stakeholders the opportunity to review the insights at their convenience.
Contact Information
Investors with inquiries can reach out to Denise Chua, SVP of Corporate Affairs, at 949-396-6830 or via email at dchua@nkgenbiotech.com. NKGen’s commitment to maintaining open communication with its investors reflects its broader dedication to transparency and growth.
Frequently Asked Questions
What is NKGen Biotech known for?
NKGen Biotech is recognized for its development of innovative NK cell therapies aimed at treating cancer.
What is the significance of the H.C. Wainwright conference for NKGen?
The H.C. Wainwright conference offers NKGen a platform to showcase its advancements and engage with potential investors.
How can investors participate in NKGen's presentation?
Investors can register to attend the conference virtually and are encouraged to submit questions during the presentation.
What types of therapies is NKGen focused on?
NKGen specializes in autologous, allogeneic, and CAR-NK natural killer cell therapies.
Where can I find more information about NKGen Biotech?
More detailed information can be found on NKGen's official website, where updates and resources are regularly made available.